Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2017 Jul-Sep;24(3):1073274817729244.
doi: 10.1177/1073274817729244.

Liver-Directed Therapies for Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma

Bela Kis  1 , Ghassan El-Haddad  1 , Rahul A Sheth  2 , Nainesh S Parikh  1 , Suvranu Ganguli  3 , Paul B Shyn  4 , Junsung Choi  1 , Karen T Brown  5
Affiliations
Review

Liver-Directed Therapies for Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma

Bela Kis et al. Cancer Control. 2017 Jul-Sep.

Abstract

Hepatocellular carcinoma (HCC) and intrahepatic cholangiocarcinoma (IHC) are primary liver cancers where all or most of the tumor burden is usually confined to the liver. Therefore, locoregional liver-directed therapies can provide an opportunity to control intrahepatic disease with minimal systemic side effects. The English medical literature and clinical trials were reviewed to provide a synopsis on the available liver-directed percutaneous therapies for HCC and IHC. Locoregional liver-directed therapies provide survival benefit for patients with HCC and IHC compared to best medical treatment and have lower comorbid risks compared to surgical resection. These treatment options should be considered, especially in patients with unresectable disease.

Keywords: chemoembolization; cholangiocarcinoma; hepatocellular carcinoma; percutaneous ablation; radioembolization.

PubMed Disclaimer

Conflict of interest statement

Declaration of Conflicting Interests: The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

References

    1. Sato KT, Lewandowski RJ, Mulcahy MF, et al. Unresectable chemorefractory liver metastases: radioembolization with 90Y microspheres—safety, efficacy, and survival. Radiology. 2008;247(2):507–515. - PubMed
    1. Tombesi P, Di Vece F, Sartori S. Resection vs thermal ablation of small hepatocellular carcinoma: What’s the first choice?. World J Radiol. 2013;5(1):1–4. - PMC - PubMed
    1. Bridgewater J, Galle PR, Khan SA, et al. Guidelines for the diagnosis and management of intrahepatic cholangiocarcinoma. J Hepatol. 2014;60(6):1268–1289. - PubMed
    1. Forner A, Llovet JM, Bruix J. Hepatocellular carcinoma. Lancet. 2012;379(9822):1245–1255. - PubMed
    1. Markowitz J. The hepatic artery. Surg Gynecol Obstet. 1952;95(5):644–646. - PubMed

MeSH terms

LinkOut - more resources